Navigation Links
NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
Date:1/25/2008

LAWRENCE, Mass., Jan. 25 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2007 on Tuesday, February 12, 2008 before the opening of the financial markets.

NxStage will also host a conference call at 9:00 a.m. Eastern Time on February 12, 2008 to discuss its fourth quarter and year end 2007 financial results. To listen to the conference call, please dial 888-713-4214 for domestic callers and 617-213-4866 for international callers. The passcode is 20821233. A replay of the conference call will be available 2 hours after the start of the call through February 26, 2008 by dialing 888-286-8010 (domestic) and 617-801-6888 (international), passcode 30075901. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://www.nxstage.com.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at http://www.nxstage.com.

Forward-Looking Stateme
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)... WASHINGTON, D.C. November 18, 2009 -- When peopl...parasites, which enter the body from the saliva of...pread to red blood cells. Inside the blood cells, ...dhesive proteins on the cell surface that change t.... , Experiments show that infected red blood cel...
(Date:11/22/2009)... HealthSmart, an innovative...nced that it has successfully completed a recapita...ompany’s other lenders. Silver Point Capita...nwich, Connecticut. This recapitalization allows ...ts business strategy. , , ...
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNewswi... statement after the Senate voted to begin full de..., (Logo: http://www.newscom.com/cgi-bin/prnh/2008...ther historic step on the road to enacting health ...l hurdle, senators will now have an opportunity to...
(Date:11/21/2009)..., , LONDON, November 21, 2009 /PRNewswire-...est Test Test Test Test Test Test Test Test Test T...est Test Test Test Test Test Test,Test Test Test T... More test More test More test More test More ...test More test More test More test More test More,...
(Date:11/21/2009)... New Haven Dental Group mer... D.D.S of Branford, CT. , ... Group, comprised of partners Dr. David Gibson, Dr... Forrester has just merged their growing practice ...man., , ,When Dr. Pickman decided he wanted to ret...
Breaking Medicine News(10 mins):Health News:Measuring and modeling blood flow in malaria 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2
...mory Crawford Long Hospital is the only site in th...rtain voice disorders that in the past might have...sium-titanyl-phosphate (KTP) laser, the device use...ews for those singers, teachers, lawyers and const...
...ealth authorities in the US are worried about yet ...squito-spread infection. Rudy Bueno, the Ch...aid that the situation may worsen if people don't ...pellants or going out at night in short-sleeve shi...
...ark Ridge, Ill. "Every second counts for anesthesi... known as malignant hyperthermia (MH)." Accordin...of the American Association of Nurse Anesthetists,...t is used to prepare the DS for use. Malig...
...ouths who receive more than 10 a week in spending ...likely to become 'problem drinkers', a survey of ...is from Liverpool John Moores University and colle...ing alcohol, of which 38% binged, 24% drank freque...
...mmonia gas leaked from the state-owned Fertilisers...al near here late Thursday, causing breathing pro...r the leak had been rectified. FACT offici...reathe. TV reporters who arrived at the sc...
...eople who use Swedish moist snuff (snus) run twice...is is the main result of a follow-up study conduct...lmost 300,000 male construction workers. The study...is an unusually malignant form of the disease. Sin...
Other Medicine News:Health News:New Laser Offers Alternative to Surgery in Treating Voice Disorders 2Health News:Health Authorities Fear West Nile Season Again in US 2Health News:Research Reveals Way to Speed Up Treatment of Deadly Malignant Hyperthermia 2Health News:Use of Swedish 'snus' is Linked to a Doubled Risk of Pancreatic Cancer 2
(Date:11/20/2009)...wswire/ -- Reportlinker.com announces that a new m...e. ,, Pipettes & Pipettors - A Global Mark...m/p0164373/Pipettes--Pipettors---A-Global-Market-P...um=pr&utm_campaign=prnewswire ,, Pipettes...any research laboratory. Large-scale applications ...
(Date:11/20/2009)...Nov. 20 Boston Scientifi...it has received 510(k) clearance from the U.S. Foo...al to market its WallFlex® Fully Covered Esop...geal strictures (obstructions) caused by tumors in...geal cancer. ,, (Photo: http://www.newscom.c...
(Date:11/20/2009)...Newswire-FirstCall/ -- Smith & Nephew ( SNN, L...ce the signing of a technology development contrac...t may lead to the creation of a fracture fixation ...the limbs of soldiers who sustain battlefield inju...ch Projects Agency (DARPA), the central research a...
Breaking Medicine Technology:Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 1Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 2Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 3Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 60858 1Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 60858 2Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 60858 3Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 2Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 3
... 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq:ACAD) ... Phase II schizophrenia co-therapy trial with ACP-...erse agonist. The trial,evaluated ACP-103 co-thera...ommonly prescribed atypical antipsychotic drug, or.... The co-therapy,arms with ACP-103 demonstrated st...
...ire-FirstCall/ -- La Jolla,Pharmaceutical Company ... data for the Phase 3 trial of Riquent(R) (abetimu...rythematosus,("lupus" or "SLE"). The updated analy...s a definitive and significant dose response,betwe...compared,with placebo (p=0.0001). These interim da...
Other Medicine Technology:Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 2Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 3Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 4Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 5Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 6La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: